Notable
CARDINAL · MK-4208/TERN-701 · Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Primary endpoint(s) modified
Also in this update: Enrollment increased: 180 → 330 participants; Interventions modified
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1/2 NCT06163430 Registry history of NCT06163430 on ClinicalTrials.gov (opens the registry)